EFPIA asked CRA to analyze existing national barriers preventing the adoption of joint reports on European relative efficacy assessments at launch (EU REA) and discuss solutions to foster the acceptance of joint reports at the national level. The project focused on nine EU countries and CRA engaged with the national trade associations in these markets to understand the barriers to using EU REA and potential solutions to overcome these barriers. This report, by Tim Wilsdon, Michele Pistollato, and Lilian Li, provides the main findings from discussions at a two-day workshop and is complemented by a set of slides with additional details. To read the report, click the link below.
MFN is rewriting the launch planning playbook: Commercial and market access strategies must integrate to succeed
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...